|
Market Closed -
TEL AVIV STOCK EXCHANGE
10:24:10 2026-11-04 EST
|
5-day change | 1st Jan Change | ||
| 2,235.00 ILa | +0.49% |
|
-8.81% | -1.11% |
| 10-06 | Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel | MT |
| 10-06 | Kamada Ltd. Announces Expansion of Biosimilars Portfolio with Launch of Two Additional Products in Israel | CI |
| Market Cap | 1.29B 0 408M 364M 333M 303M 570M 38.56B 583M 3.98B 1.6B 20.41B 1.53B 1.5B 64.64B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 1.29B 0 408M 364M 333M 303M 570M 38.56B 583M 3.98B 1.6B 20.41B 1.53B 1.5B 64.64B | EV / Sales 2026 * |
2.1x | EV / Sales 2027 * | 1.86x |
| Free-Float |
54.72% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
TEL AVIV STOCK EXCHANGE
| KMDA | Delayed | |
Nasdaq
| KMDA | Delayed | |
|
CBOE
| KMDA | Real-time |
Last Transcript: Kamada Ltd.
| 1 day | +0.49% | ||
| 1 week | -8.81% | ||
| Current month | -8.25% | ||
| 1 month | -12.04% | ||
| 3 months | +2.52% | ||
| 6 months | -8.55% | ||
| Current year | -1.11% |
| 1 week | 2,197 |  | 2,459 |
| 1 month | 2,197 | | 2,546 |
| Current year | 2,013 | | 2,890 |
| 1 year | 1,956 | | 2,890 |
| 3 years | 1,712 | | 3,045 |
| 5 years | 1,309 | | 3,045 |
| 10 years | 1,309 | | 4,500 |
| Manager | Title | Age | Since |
|---|---|---|---|
Amir London
CEO | Chief Executive Officer | 58 | 2015-06-30 |
Chaime Orlev
DFI | Director of Finance/CFO | 56 | 2017-12-30 |
Eran Nir
COO | Chief Operating Officer | 54 | 2016-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
David Tsur
BRD | Director/Board Member | 75 | 1990-12-12 |
Leon Recanati
CHM | Chairman | 77 | 2013-03-06 |
| Chairman | 55 | 2020-08-11 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/14/26 | Exercice | VP Quality | 61,323 | 0.1063% | ||
| 9/14/26 | Sell | Founder | -22,827 | 0.0396% | ||
| 9/14/26 | Exercice | General Counsel | 23,459 | 0.0407% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.49% | -8.81% | +0.22% | +25.77% | 408M | |
| +0.61% | +10.07% | +56.36% | +149.73% | 1,263B | |
| +3.81% | +1.95% | +47.88% | +82.58% | 665B | |
| +3.09% | +3.09% | +36.56% | +108.48% | 521B | |
| +1.25% | -0.73% | +49.96% | +66.87% | 387B | |
| +3.93% | +6.69% | +79.30% | +45.44% | 371B | |
| +2.10% | +3.90% | +32.30% | +61.10% | 310B | |
| +1.92% | +9.87% | +11.94% | +36.55% | 293B | |
| +3.73% | +5.90% | +61.27% | +77.31% | 259B | |
| +4.19% | +9.60% | +41.85% | +113.85% | 216B | |
| Average | +2.51% | +4.15% | +41.77% | +76.77% | 428.58B | |
| Weighted average by Cap. | +2.32% | +5.96% | +48.83% | +97.44% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 613M 0 194M 173M 158M 144M 271M 18.33B 277M 1.89B 759M 9.7B 728M 712M 30.73B | 692M 0 219M 195M 179M 163M 306M 20.7B 313M 2.14B 857M 10.95B 822M 804M 34.7B |
| Net income | 83.94M 0 26.55M 23.66M 21.7M 19.72M 37.07M 2.51B 37.91M 259M 104M 1.33B 99.65M 97.52M 4.21B | 102M 0 32.3M 28.79M 26.4M 23.99M 45.1M 3.05B 46.13M 316M 126M 1.62B 121M 119M 5.12B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-04 | ILA 2,235.00 | +0.49% | 132,466 |
| 26-11-03 | ILA 2,224.00 | -3.30% | 264,409 |
| 26-11-02 | ILA 2,300.00 | -5.58% | 85,105 |
| 26-10-30 | ILA 2,436.00 | -0.57% | 26,177 |
| 26-10-29 | ILA 2,450.00 | -0.04% | 69,558 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- KMDA Stock
Select your edition
All financial news and data tailored to specific country editions
